Novartis has turned to Ionis for another cardiovascular disease drug, putting $60 million down for a follow-up to lipoprotein(a)-targeting drug pelacarsen, which is now in phase 3 testing.

Novartis’ Akcea-partnered pelacarsen and Amgen’s olpasiran are both in phase 3 development, meaning they could reach the market in a couple of years. That’s important, as Lp(a) increases the ...

It gives patients hope." One of those experimental drugs is called pelacarsen, from drugmaker Novartis. Earlier studies showed it significantly drove down Lp(a) levels in 98% of people taking it. The ...

While statins can reduce LDL levels and ASCVD events, high Lp(a) poses an independent risk that will need attention, too.

The other two major markets Ionis is targeting - this time with partners - are cardiovascular disease ("CVD"), through Pelacarsen, partnered with Swiss Pharma Novartis (NVS), and hepatitis B ...

Hello. My question is on the broader cardiovascular portfolio now at Novartis, particularly focusing on the pipeline. I mean, ...

As a host of generics circle the gates, Novartis has lost another bid to waylay MSN Pharmaceuticals’ copycat of the Swiss pharma’s top-selling drug Entresto. In a court decision filed this ...

Novartis' drug segment is poised for steady ... close to $1 billion for remibrutinib (multiple sclerosis data in 2026), pelacarsen (cardiovascular outcomes data in 2025), and rare disease drug ...

Oct 16 (Reuters) - Novartis (NOVN.S), opens new tab has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by blocking regulators from ...

Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. The deal, which features $1.1 billion in milestones, covers the global rights to a small ...

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA) recommended granting approval to the breast cancer drug Kisqali ...